DOCSLIB.ORG

ABC of Transfusion THERAPEUTIC APHERESIS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABC of Transfusion THERAPEUTIC APHERESIS ABC of Transfusion BMJ: first published as 10.1136/bmj.300.6725.662 on 10 March 1990. Downloaded from THERAPEUTIC APHERESIS S J Urbaniak, E A Robinson Therapeutic apheresis is the removal ofblood or one ofits components from the body for clinical purposes, usually by automated blood cell separators. Cytapheresis removes cellular constituents, whereas in plasmapheresis the cells are returned and the plasma retained. When large volumes of material are removed some form of replacement is required and the procedure is one tAt of "exchange" (for example, red cell exchange or plasma exchange); the terms plasmapheresis and plasma exchange are often (loosely) used interchangeably. The procedures are not curative but are adjuncts to conventional treatment in which relief of symptoms or control of pathological processes may be achieved quickly. Rarely, long term control of a disease may be accomplished with less morbidity than with chemotherapy, as in the Dr Robinson giving her 50th donation of hyperviscosity of macroglobulinaemia. plasma. Apheresis can affect only the intravascular compartment, and the efficacy of treatment will depend on the volume of blood processed, the rapidity with which the cells or plasma components can be mobilised from the extravascular compartments and the balance between catabolism and synthesis, on the one hand, and the constituents of the replacement fluid on the other. http://www.bmj.com/ Cytapheresis Red cells In the strict sense, simple venesection or on 26 September 2021 by guest. Protected copyright. Functions of plasma exchange manual exchange transfusion is a form of Removal of: cytapheresis that has been used for many years to * Antibodies-alloantibodies Anti-Rh(D) (Rh haemolytic treat polycythaemia, the acute crisis in sickle cell disease) -autoantibodies Goodpasture's disease; disease, and haemolytic disease of the newborn. myasthenia gravis Automated procedures aid the rapid, isovolaemic -immune complexes Systemic lupus removal of large quantities of abnormal cells or erythematosus unusually high concentrations of cells, or both. * Excessive or abnormal constituents Paraproteins (multiple Rarely, patients with life threatening myeloma) severe in Phytanic acid (Refsum's autoimmune haemolysis, parasitaemia disease) malaria or babesiosis, or acute porphyria have Familial been managed successfully by hypercholesterolaemia erythrocytapheresis. Harvest ofreticulocytes and * Protein bound toxins and drugs ax-Amanitin (mushroom young red cell "neocytes" for maintenance poisoning) transfusion in-for example, thalassaemia-is * Antigens Drug induced systemic lupu5Is under investigation. erythematosus Replacement of: Platelets * Factors in thrombotic thrombocytopenic purpura and haemolytic Thrombocytapheresis may be used to lower uraemic syndrome the platelet count rapidly in patients with * Normal immunoglobulin myeloproliferative disorders and platelet counts * Pseudocholinesterase of more than 1000 x 109/l, such as polycythaemia rubra vera, primary thrombocythaemia, and chronic granulocytic leukaemia. The main 662 BMJ VOLUME 300 10 MARCH 1990 concern is to prevent the development of thrombotic or haemorrhagic complications before conventional chemotherapy can control platelet production, which usually takes two to three weeks. Two or more procedures - either on consecutive or alternate days - are usually required to achieve adequate reduction in the platelet count. Asymptomatic thrombocytosis does not require removal ofplatelets unless the patient has a BMJ: first published as 10.1136/bmj.300.6725.662 on 10 March 1990. Downloaded from Synthesis prolonged bleeding time and is about to undergo an operation. Long term thrombocytapheresis in chronic diseases is not effective. Extravascular ) (interstitial space) a Plasma 12 Q* ~ volume Plasma exchange 3 (usually 3 - 4 1) Leucocytes 10 Leucocytapheresis is indicated in various forms ofleukaemia when white cell count is greater than 100 x 109/1. An extremely high white cell count will Catabolism promote leucostasis with vascular occlusion in the microcirculation, and this can result in neurological abnormalities, thrombotic episodes, Efficiency of depletion by plasmapheresis. pulmonary dysfunction, and priapism. Leucocytapheresis can rapidly Theoretically, 63% of the intravascular reduce both the white cell count and the blood viscosity and may be of substance is removed by a single volume plasma exchange. The duration of reduction benefit in the early management of leukaemia because it can prevent depends on: (a) intravascular/extravascular neurological and respiratory impairment while the cytotoxic chemotherapy distribution of substance; (b) transcapillary is taking effect. exchange between intravascular and Reducing the number ofcirculating leukaemia cells ("debulking") before extravascular compartments; (c) fractional starting chemotherapy will reduce the risks of hyperuricaemia, and may catabolic rate (equivalent to synthetic rate at steady state); and (d) rate of synthesis. increase the efficacy of chemotherapy in patients with acute myelocytic leukaemia. Even in the absence of leucostasis, early cytapheresis can bring symptomatic relief to a patient with night sweats, pruritis, and abdominal pain as a result of enlargement of the spleen and liver. Long term cytapheresis to maintain a low white count, however, is not justified. Cytapheresis may also be used to harvest stem cells from blood for subsequent autologous transfusion, as an alternative to bone marrow. Plasmapheresis/plasma exchange Diseases in which plasma exchange is often ofbenefit* Plasmapheresis is the selective removal of small volumes (<600 ml) of plasma that does not Pathogenic factors (which may be fluid It is require intravenous replacement. http://www.bmj.com/ used to monitor efficiency of routinely carried out to harvest plasma from Disease treatment or progress of disease) blood donors. Plasma exchange is the removal of Hyperviscosity syndrome Monoclonal immunoglobulins a larger volume of plasma, which requires (Waldenstrom's (hyperviscosity) replacement by an appropriate fluid to maintain macroglobulinaemia, multiple homoeostasis. myeloma) Myasthenia gravis Anti-ACh receptors Goodpasture's syndrome Anti-glomerular basement membrane on 26 September 2021 by guest. Protected copyright. Cryoglobulinaemia Cryoglobulins Purpose ofplasma exchange Haemophilia with inhibitors Anti-factor Vil inhibitor The aim is to remove, or reduce to a minimum, Refsum's disease Phytanic acid Thrombotic thrombocytopenic those constituents of plasma that cause or purpura Unknown aggravate a disease. To be of benefit plasma Cold agglutinin haemolytic anaemia Agglutinin exchange must remove some pathogenic material Poisons (for example, mushrooms) a-Amanitin that is known to be present in plasma in Drugs Parathion-methyl, digoxin appreciable quantities, the removal must be more rapid than renewal, the underlying disease *Not necessarily in all cases and usually only when acute symptorms have not responded to conventional treatment. should be sufficiently serious to outweigh the risks of exchange, and there should be a reasonable chance of recovery. The most common diseases are immunological, and an antibody (IgG or IgM), an Diseases in which plasma exchange may be antigen, or an immune complex is removed. To prevent rebound synthesis of benefit immunosuppression must be combined with plasma exchange as plasma * Familial hypercholesterolaemia exchange alone is ineffective. In some instances there is a deficiency of, or * Acute Guillain-Barre syndrome defect in, some plasma factors that can effectively be replaced by large * Immune complex vasculitis- volume plasma exchange with fresh frozen plasma -for example, in Systemic lupus erythematosus Rheumatoid arthritis patients with thrombotic thrombocytopenic purpura. * Rapidly progressive glomerulonephritis * Rh haemolytic disease Many diseases have been treated by plasma exchange, but it is most * Post-transfusion purpura successful when there is a measurable, well characterised, pathogenic * Bullous pemphigoid substance present which causes acute tissue or organ damage that is reversible or preventable by timely intervention. BMJ VOLUME 300 10 MARCH 1990 663 Fresh frozen plasma Plasma Volume andfrequency ofplasma exchange exchangel I t t I I Normal healthy donors undergoing plasmapheresis do not require (mean 2 31, total 39 1) An nniocentesis i0.08 0.046 j 0.08 replacement of fluids. If more than 1 litre is removed, however, replacement of albumin is necessary, otherwise vasular colloid osmotic pressure will fall and haemodilution and peripheral oedema will occur. The choice of replacement fluid is based on cost, convenience, availability, and BMJ: first published as 10.1136/bmj.300.6725.662 on 10 March 1990. Downloaded from volume removed. Partial substitution with 0-9% saline or colloids (such as hydroxyethyl starch or gelatins), or both, is acceptable. 0 c a)0 c,] The volume and frequency of plasma exchange is determined by the pathophysiology of the "undesirable" factors. There may be unwanted side effects from the removal of normal constitutents that may be of sufficient severity to require specific replacement. Albumin, the immunoglobulins, complement, and coagulation factors are the main components of plasma Gestation (weeks) proteins that are affected by large volume plasma exchange. A single Note rapid rise in anti-D after stimulus of volume plasma exchange (40 mg/kg) will reduce the concentrations of aminocentesis released Rh positive red cells
Load more

Recommended publications
  • Transfusion Service Introduction Blood/Blood Products Requests and Turnaround Time Expectations
    Transfusion Service Introduction All blood products and blood components are supplied to UnityPoint Health-Meriter Hospital by the American Red Cross Blood Services. Pathology consultation is available regarding blood and/or components and dosages. ABO and Rho(D)—specific type is used whenever possible for leuko-poor packed cell transfusions. ABO-compatible blood is used for all plasma and platelet components whenever possible. For any orders involving HLA-matched components, the patient must have been HLA typed (sent to the American Red Cross) a minimum of 48 hours prior to intended infusion of the component. HLA typing is only required once. Blood components that are thawed, pooled, washed, volume-reduced, or deglycerolized for a patient will be charged to the patient even if not transfused. The charge is done because these components may not be suitable for another patient. Examples include: Autologous or directed donations Pooled cryoprecipitate 4-hour expiration Thawed fresh frozen plasma 24-hour expiration Thawed cryoprecipitate 6-hour expiration Deglycerolized red cells 24-hour expiration Washed red cells 24-hour expiration All blood components must be completely infused within 4 hours of release from UnityPoint Health-Meriter Laboratories Blood Bank, or be infused within the expiration time. Refer to UnityPoint Health -Meriter’s Blood and Blood Products Transfusion Policy #123 for additional information located on MyMeriter. Blood/Blood Products Requests and Turnaround Time Expectations Requests from UnityPoint Health-Meriter Hospital are entered in the hospital computer system and print in the UnityPoint Health- Meriter Laboratories Blood Bank. For the comfort of the patient, it is important to coordinate collection for other tests with Blood Bank specimens.
    [Show full text]
  • Fluid Resuscitation Therapy for Hemorrhagic Shock
    CLINICAL CARE Fluid Resuscitation Therapy for Hemorrhagic Shock Joseph R. Spaniol vides a review of the 4 types of shock, the 4 classes of Amanda R. Knight, BA hemorrhagic shock, and the latest research on resuscita- tive fluid. The 4 types of shock are categorized into dis- Jessica L. Zebley, MS, RN tributive, obstructive, cardiogenic, and hemorrhagic Dawn Anderson, MS, RN shock. Hemorrhagic shock has been categorized into 4 Janet D. Pierce, DSN, ARNP, CCRN classes, and based on these classes, appropriate treatment can be planned. Crystalloids, colloids, dopamine, and blood products are all considered resuscitative fluid treat- ment options. Each individual case requires various resus- ■ ABSTRACT citative actions with different fluids. Healthcare Hemorrhagic shock is a severe life-threatening emergency professionals who are knowledgeable of the information affecting all organ systems of the body by depriving tissue in this review would be better prepared for patients who of sufficient oxygen and nutrients by decreasing cardiac are admitted with hemorrhagic shock, thus providing output. This article is a short review of the different types optimal care. of shock, followed by information specifically referring to hemorrhagic shock. The American College of Surgeons ■ DISTRIBUTIVE SHOCK categorized shock into 4 classes: (1) distributive; (2) Distributive shock is composed of 3 separate categories obstructive; (3) cardiogenic; and (4) hemorrhagic. based on their clinical outcome. Distributive shock can be Similarly, the classes of hemorrhagic shock are grouped categorized into (1) septic; (2) anaphylactic; and (3) neu- by signs and symptoms, amount of blood loss, and the rogenic shock. type of fluid replacement. This updated review is helpful to trauma nurses in understanding the various clinical Septic shock aspects of shock and the current recommendations for In accordance with the American College of Chest fluid resuscitation therapy following hemorrhagic shock.
    [Show full text]
  • Patient's Guide to Blood Transfusions
    Health Information For Patients and the Community A Patient’s Guide to Blood Transfusions Your doctor may order a blood transfusion as part of your therapy. This brochure will focus on frequently asked questions about blood products, transfusions, and the risks and benefits of the blood transfusion. PLEASE NOTE: This information is not intended to replace the medical advice of your doctor or health care provider and is intended for educational purposes only. Individual circumstances will affect your individual risks and benefits. Please discuss any questions or concerns with your doctor. What is a blood transfusion? A blood transfusion is donated blood given to patients with abnormal blood levels. The patient may have abnormal blood levels due to blood loss from trauma or surgery, or as a result of certain medical problems. The transfusion is done with one or more of the following parts of blood: red blood cells, platelets, plasma, or cryoprecipitate. What are the potential benefits of a blood transfusion? If your body does not have enough of one of the components of blood, you may develop serious life-threatening complications. • Red blood cells carry oxygen through your body to your heart and brain. Adequate oxygen is very important to maintain life. • Platelets and cryoprecipitate help to prevent or control bleeding. • Plasma replaces blood volume and also may help to prevent or control bleeding. How safe are blood transfusions? Blood donors are asked many questions about their health, behavior, and travel history in order to ensure that the blood supply is as safe as it can be. Only people who pass the survey are allowed to donate.
    [Show full text]
  • Patient Information Leaflet – Plasma Exchange Procedure
    Therapeutic Apheresis Services Patient Information Leaflet – Plasma Exchange Procedure Introduction Antibodies, which normally help to protect you from infection, can begin to attack your own This leaflet has been written to give patients healthy cells, or an over production of proteins can information about plasma exchange (sometimes cause your blood to become thicker and slow down called plasmapheresis). If you would like any more the blood flow throughout your body. A plasma information or have any questions, please ask the exchange can help improve your symptoms, doctors and nurses involved in your treatment at although this may not happen immediately. the NHS Blood and Transplant (NHSBT) Therapeutic Apheresis Services Unit. Although plasma exchange may help with symptoms, it will not normally cure your condition When you have considered the information given as it does not switch off the production of the in this leaflet, and after we have discussed the harmful antibodies or proteins. It is likely that procedure and its possible risks with you, we will this procedure will form only one part of your ask you to sign a consent form to indicate that you treatment. are happy for the procedure to go ahead. Before any further procedures we will again check that you are happy to proceed. How do we perform Plasma Exchange? What is a plasma exchange? Plasma exchange is performed using a machine Blood is made up of red cells, white cells and called a Blood Cell Separator which can separate platelets which are carried around in fluid called blood into its various parts. The machine separates plasma.
    [Show full text]
  • Intraoperative Fluid Therapy and Pulmonary Complications
    ■ Feature Article Intraoperative Fluid Therapy and Pulmonary Complications KRZYSZTOF SIEMIONOW, MD; JACEK CYWINSKI, MD; KRZYSZTOF KUSZA, MD, PHD; ISADOR LIEBERMAN, MD, MBA, FRCSC abstract Full article available online at ORTHOSuperSite.com. Search: 20120123-06 The purpose of this study was to evaluate the effects of intraoperative fl uid therapy on length of hospital stay and pulmonary complications in patients undergoing spine surgery. A total of 1307 patients were analyzed. Sixteen pulmonary complications were observed. Patients with a higher volume of administered crystalloids, colloids, and total intravenous fl uids were more likely to have postoperative respiratory com- plications: the odds of postoperative respiratory complications increased by 30% with an increase of 1000 mL of crystalloid administered. The best cutoff point for total fl uids was 4165 mL, with a sensitivity of 0.8125 and specifi city of 0.7171, for postoperative pulmonary complications. A direct correlation existed between fl uids and length of stay: patients who received Ͼ4165 mL of total fl uids had an average length of stay of 3.88Ϯ4.66 days vs 2.3Ϯ3.9 days for patients who received Ͻ4165 mL of total fl uids (PϽ.0001). This study should be considered as hypothesis-generating to design a prospective trial comparing high vs low intraoperative fl uid regiments for patients undergoing spine surgery. Dr Siemionow is from the Department of Orthopaedic Surgery, University of Illinois, Chicago, Illinois; Dr Cywinski is from the Department of Anesthesia, Cleveland Clinic, Cleveland, Ohio; Dr Kusza is from the Department of Anesthesia, Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland; and Dr Lieberman is from Texas Back Institute, Plano, Texas.
    [Show full text]
  • Terminology Resource File
    Terminology Resource File Version 2 July 2012 1 Terminology Resource File This resource file has been compiled and designed by the Northern Assistant Transfusion Practitioner group which was formed in 2008 and who later identified the need for such a file. This resource file is aimed at Assistant Transfusion Practitioners to help them understand the medical terminology and its relevance which they may encounter in the patient’s medical and nursing notes. The resource file will not include all medical complaints or illnesses but will incorporate those which will need to be considered and appreciated if a blood component was to be administered. The authors have taken great care to ensure that the information contained in this document is accurate and up to date. Authors: Jackie Cawthray Carron Fogg Julia Llewellyn Gillian McAnaney Lorna Panter Marsha Whittam Edited by: Denise Watson Document administrator: Janice Robertson ACKNOWLEDGMENTS We would like to acknowledge the following people for providing their valuable feedback on this first edition: Tony Davies Transfusion Liaison Practitioner Rose Gill Transfusion Practitioner Marie Green Transfusion Practitioner Tina Ivel Transfusion Practitioner Terry Perry Transfusion Specialist Janet Ryan Transfusion Practitioner Dr. Hazel Tinegate Consultant Haematologist Reviewed July 2012 Next review due July 2013 Version 2 July 2012 2 Contents Page no. Abbreviation list 6 Abdominal Aortic Aneurysm (AAA) 7 Acidosis 7 Activated Partial Thromboplastin Time (APTT) 7 Acquired Immune Deficiency Syndrome
    [Show full text]
  • Update on Volume Resuscitation Hypovolemia and Hemorrhage Distribution of Body Fluids Hemorrhage and Hypovolemia
    11/7/2015 HYPOVOLEMIA AND HEMORRHAGE • HUMAN CIRCULATORY SYSTEM OPERATES UPDATE ON VOLUME WITH A SMALL VOLUME AND A VERY EFFICIENT VOLUME RESPONSIVE PUMP. RESUSCITATION • HOWEVER THIS PUMP FAILS QUICKLY WITH VOLUME LOSS AND IT CAN BE FATAL WITH JUST 35 TO 40% LOSS OF BLOOD VOLUME. HEMORRHAGE AND DISTRIBUTION OF BODY FLUIDS HYPOVOLEMIA • TOTAL BODY FLUID ACCOUNTS FOR 60% OF LEAN BODY WT IN MALES AND 50% IN FEMALES. • BLOOD REPRESENTS ONLY 11-12 % OF TOTAL BODY FLUID. CLINICAL MANIFESTATIONS OF HYPOVOLEMIA • SUPINE TACHYCARDIA PR >100 BPM • SUPINE HYPOTENSION <95 MMHG • POSTURAL PULSE INCREMENT: INCREASE IN PR >30 BPM • POSTURAL HYPOTENSION: DECREASE IN SBP >20 MMHG • POSTURAL CHANGES ARE UNCOMMON WHEN BLOOD LOSS IS <630 ML. 1 11/7/2015 INFLUENCE OF ACUTE HEMORRHAGE AND FLUID RESUSCITATION ON BLOOD VOLUME AND HCT • COMPARED TO OTHERS, POSTURAL PULSE INCREMENT IS A SENSITIVE AND SPECIFIC MARKER OF ACUTE BLOOD LOSS. • CHANGES IN HEMATOCRIT SHOWS POOR CORRELATION WITH BLOOD VOL DEFICITS AS WITH ACUTE BLOOD LOSS THERE IS A PROPORTIONAL LOSS OF PLASMA AND ERYTHROCYTES. MARKERS FOR VOLUME CHEMICAL MARKERS OF RESUSCITATION HYPOVOLEMIA • CVP AND PCWP USED BUT EXPERIMENTAL STUDIES HAVE SHOWN A POOR CORRELATION BETWEEN CARDIAC FILLING PRESSURES AND VENTRICULAR EDV OR CIRCULATING BLOOD VOLUME. Classification System for Acute Blood Loss • MORTALITY RATE IN CRITICALLY ILL PATIENTS Class I: Loss of <15% Blood volume IS NOT ONLY RELATED TO THE INITIAL Compensated by transcapillary refill volume LACTATE LEVEL BUT ALSO THE RATE OF Resuscitation not necessary DECLINE IN LACTATE LEVELS AFTER THE TREATMENT IS INITIATED ( LACTATE CLEARANCE ). Class II: Loss of 15-30% blood volume Compensated by systemic vasoconstriction 2 11/7/2015 Classification System for Acute Blood FLUID CHALLENGES Loss Cont.
    [Show full text]
  • Laboratory Best Transfusion Practice for Neonates, Infants and Children
    Laboratory Best Transfusion Practice for Neonates, Infants and Children This summary guidance should be used in conjunction with the appropriate 20161 and 20122 BSH Guidelines and laboratory SOPs Compatibility testing Neonates and infants < 4 months Obtain neonatal and maternal transfusion history (including any fetal transfusions) for all admissions. Obtain a maternal sample for initial testing where possible, in addition to the patient sample. Red cell selection: no maternal antibodies present Select appropriate group and correct neonatal specification red cells. Group O D-negative red cells may be issued electronically without serological crossmatch. If the laboratory does not universally select group O D-negative red cells for this age group, blood group selection should either be controlled by the LIMS or an IAT crossmatch should be performed using maternal or neonatal plasma to serologically confirm ABO compatibility with both mother and neonate. Red cell selection: where there is maternal antibody Select appropriate group red cells, compatible with maternal alloantibody/ies. An IAT crossmatch should be performed using the maternal plasma. If it is not possible to obtain a maternal sample it is acceptable to crossmatch antigen-negative units against the infant’s plasma. Where paedipacks are being issued from one donor unit it is only necessary to crossmatch the first split pack. Subsequent split packs from this multi-satellite unit can be automatically issued without further crossmatch until the unit expires or the infant is older than 4 months. If packs from a different donor are required, an IAT crossmatch should be performed. Infants and children ≥ 4 months For infants and children from 4 months of age, pre-transfusion testing and compatibility procedures should be performed as recommended for adults.
    [Show full text]
  • Fluid Resuscitation for Hemorrhagic Shock in Tactical Combat Casualty Care TCCC Guidelines Change 14-01 – 2 June 2014
    Fluid Resuscitation for Hemorrhagic Shock in Tactical Combat Casualty Care TCCC Guidelines Change 14-01 – 2 June 2014 Frank K. Butler, MD; John B. Holcomb, MD; Martin A. Schreiber, MD; Russ S. Kotwal, MD; Donald A. Jenkins, MD; Howard R. Champion, MD, FACS, FRCS; F. Bowling; Andrew P. Cap, MD; Joseph J. Dubose, MD; Warren C. Dorlac, MD; Gina R. Dorlac, MD; Norman E. McSwain, MD, FACS; Jeffrey W. Timby, MD; Lorne H. Blackbourne, MD; Zsolt T. Stockinger, MD; Geir Strandenes, MD; Richard B, Weiskopf, MD; Kirby R. Gross, MD; Jeffrey A. Bailey, MD ABSTRACT This report reviews the recent literature on fluid resusci- to hypotensive resuscitation, the use of DP, adverse ef- tation from hemorrhagic shock and considers the appli- fects resulting from the administration of both crystal- cability of this evidence for use in resuscitation of combat loids and colloids, prehospital resuscitation with thawed casualties in the prehospital Tactical Combat Casualty plasma and red blood cells (RBCs), resuscitation from Care (TCCC) environment. A number of changes to the combined hemorrhagic shock and traumatic brain in- TCCC Guidelines are incorporated: (1) dried plasma jury (TBI), balanced blood component therapy in DCR, (DP) is added as an option when other blood compo- the benefits of fresh whole blood (FWB) use, and re- nents or whole blood are not available; (2) the wording suscitation from hemorrhagic shock in animal models is clarified to emphasize that Hextend is a less desir- where the hemorrhage is definitively controlled prior to able option than whole blood, blood components, or resuscitation. DP and should be used only when these preferred op- tions are not available; (3) the use of blood products Additionally, recently published studies describe an in certain Tactical Field Care (TFC) settings where this increased use of blood products by coalition forces in option might be feasible (ships, mounted patrols) is dis- Afghanistan during Tactical Evacuation (TACEVAC) cussed; (4) 1:1:1 damage control resuscitation (DCR) Care and even in TFC.
    [Show full text]
  • Albumin Stewardship for Fluid Replacement in Plasmapheresis Kamarena Sankar, Pharm.D
    Albumin stewardship for fluid replacement in plasmapheresis Kamarena Sankar, Pharm.D. PGY-1 Resident Pharmacist Holmes Regional Medical Center Disclosure Statement .These individuals have nothing to disclose concerning possible financial or personal relationships with commercial entities (or their competitors) that may be referenced in this presentation: .Kamarena Sankar, Pharm.D. .Jay Pauly, Pharm.D. .Michael Sanchez, Pharm.D. Presentation Objective .Understand the post-implementation safety and cost data of an Albumin Stewardship Initiative for fluid replacement in plasmapheresis Background .Definition: Plasmapheresis is removal of a patient’s own plasma .Varies between patients .This also removes potentially harmful substances: .Immunoglobulin .Autoantibodies .Immune complexes .Monoclonal paraproteins .Protein-bound toxins Hollie M. Reeves Br J Haematol. 2014;164.3:342-351. Indications Guillain-Barré Syndrome, ANCA glomerulonephritis, Myasthenia Gravis, Autoimmune Encephalitis, Renal First-Line Transplantation, Thrombotic Thrombocytopenic Purpura (TTP) Cryoglobinemia, Familial Hypercholesterolemia, Second-Line Multiple Sclerosis Role Not Heparin-induced Thrombocytopenia (HIT), Nephrogenic Established Systemic Fibrosis Ineffective or Psoriasis, Dermatomyositis/Polymyositis Harmful J Schwartz. J Clin Apher. 2016;31.3:149-338. Background .Fluid Replacement during plasmapheresis: .Necessary to avoid hypotension .Institution practice: .Albumin 5% 3,000 mL .IV room processing time .Multiple manipulations .High cost J Schwartz. J Clin Apher. 2016;31.3:149-338. Background Literature .Yamada (2017) .Albumin in combination with normal saline .5:1, 4:1, 5:2, 1:1 .3 patients, 12 procedures .No blood pressure differences .Albumin only fluid replacement .Albumin-normal saline combination replacement .McCullough (1982) .Options for fluid replacement .Normal saline .Albumin Chisa Yamada. J Clin Apher. 2017;32.1:5-11. J McCullough. Vox Sang.
    [Show full text]
  • Getting Ready for Apheresis
    Page 1 of 2 Getting Ready for Apheresis For Patients What is apheresis? How does it work? Apheresis [AY-fur-EE-sis] is the removal of certain • You will sit in a chair or lie in a bed. blood cells. • We place a needle in the vein of each arm. We We take blood from your vein and pass it through a remove blood from one arm and pass it through machine. The machine collects a part of your blood. a machine. The rest of the blood is returned to your body. • As the blood leaves your body, it is treated There are several types of apheresis. Your doctor will with medicines (citrate and heparin) to tell you which type you will have: prevent clotting. ☐ Red blood cell exchange removes some of your • The machine spins, separating the parts of the red blood cells. These are replaced by a donor’s blood. This allows us to collect the needed cells. red blood cells. This takes 2 to 3 hours. • The rest of the blood flows back into your body ☐ Plasma exchange removes plasma from your through the needle in your other arm. blood. The plasma is replaced with a donor’s plasma, 5% albumin (a protein) or both. This If your veins are too small for needles, you may need takes 2 to 3 hours. to have a catheter (a tiny tube) placed into a larger vein. The vein is usually in the lower neck, upper ☐ Plateletpheresis removes some of your platelets chest or groin (area between your leg and trunk).
    [Show full text]
  • 6 Alternatives to Allogeneic Blood Transfusions
    Best Practice & Research Clinical Anaesthesiology Vol. 21, No. 2, pp. 221–239, 2007 doi:10.1016/j.bpa.2007.02.004 available online at http://www.sciencedirect.com 6 Alternatives to allogeneic blood transfusions Andreas Pape* Dr. med. Clinic of Anaesthesiology, Intensive Care Medicine and Pain Management, J. W. Goethe University Hospital Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany Oliver Habler Professor Dr. med. Department Head Clinic of Anaesthesiology, Surgical Intensive Care Medicine and Pain Management, Nordwest-Krankenhaus, Steinbacher Hohl 2-26, 60488 Frankfurt am Main Germany Inherent risks and increasing costs of allogeneic transfusions underline the socioeconomic rel- evance of safe and effective alternatives to banked blood. The safety limits of a restrictive trans- fusion policy are given by a patient’s individual tolerance of acute normovolaemic anaemia. Iatrogenic attempts to increase tolerance of anaemia are helpful in avoiding premature blood transfusions while at the same time maintaining adequate tissue oxygenation. Autologous trans- fusion techniques include preoperative autologous blood donation (PAD), acute normovolaemic haemodilution (ANH), and intraoperative cell salvage (ICS). The efficacy of PAD and ANH can be augmented by supplemental iron and/or erythropoietin. PAD is only cost-effective when based on a meticulous donation/transfusion plan calculated for the individual patient, and still carries the risk of mistransfusion (clerical error). In contrast, ANH has almost no risks and is more cost-effective. A significant reduction in allogeneic blood transfusions can also be achieved by ICS. Currently, some controversy regarding contraindications of ICS needs to be resolved. Artificial oxygen carriers based on perfluorocarbon (PFC) or haemoglobin (haemoglobin-based oxygen carriers, HBOCs) are attractive alternatives to allogeneic red blood cells.
    [Show full text]